BR112022001140A2 - Métodos para avaliar se um paciente tem endometriose ou está em risco de desenvolver endometriose, selecionar um paciente para terapia e monitorar um paciente que sofre de endometriose ou que está sendo tratado para endometriose - Google Patents

Métodos para avaliar se um paciente tem endometriose ou está em risco de desenvolver endometriose, selecionar um paciente para terapia e monitorar um paciente que sofre de endometriose ou que está sendo tratado para endometriose

Info

Publication number
BR112022001140A2
BR112022001140A2 BR112022001140A BR112022001140A BR112022001140A2 BR 112022001140 A2 BR112022001140 A2 BR 112022001140A2 BR 112022001140 A BR112022001140 A BR 112022001140A BR 112022001140 A BR112022001140 A BR 112022001140A BR 112022001140 A2 BR112022001140 A2 BR 112022001140A2
Authority
BR
Brazil
Prior art keywords
endometriosis
patient
methods
therapy
risk
Prior art date
Application number
BR112022001140A
Other languages
English (en)
Inventor
Aikaterini Georgopoulou
Felix Gruenewald
Heike Wegmeyer
Martin Hund
Martin Klammer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112022001140A2 publication Critical patent/BR112022001140A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

métodos para avaliar se um paciente tem endometriose ou está em risco de desenvolver endometriose, selecionar um paciente para terapia e monitorar um paciente que sofre de endometriose ou que está sendo tratado para endometriose. a presente invenção se refere a métodos para avaliar se uma paciente tem endometriose ou está em risco de desenvolver endometriose, a métodos para selecionar uma paciente para terapia, e método para monitorar uma paciente que sofre de endometriose ou está sendo tratada para endometriose por determinação da quantidade ou concentração de s100a12 em uma amostra da paciente, e comparando a quantidade ou concentração determinada com uma referência.
BR112022001140A 2019-07-22 2020-07-20 Métodos para avaliar se um paciente tem endometriose ou está em risco de desenvolver endometriose, selecionar um paciente para terapia e monitorar um paciente que sofre de endometriose ou que está sendo tratado para endometriose BR112022001140A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19187477 2019-07-22
PCT/EP2020/070426 WO2021013783A1 (en) 2019-07-22 2020-07-20 S100a12 as blood biomarker for the non-invasive diagnosis of endometriosis

Publications (1)

Publication Number Publication Date
BR112022001140A2 true BR112022001140A2 (pt) 2022-03-15

Family

ID=67438325

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001140A BR112022001140A2 (pt) 2019-07-22 2020-07-20 Métodos para avaliar se um paciente tem endometriose ou está em risco de desenvolver endometriose, selecionar um paciente para terapia e monitorar um paciente que sofre de endometriose ou que está sendo tratado para endometriose

Country Status (7)

Country Link
US (1) US20220137069A1 (pt)
EP (1) EP4004552A1 (pt)
JP (1) JP7315781B2 (pt)
KR (1) KR20220024699A (pt)
CN (1) CN114144671A (pt)
BR (1) BR112022001140A2 (pt)
WO (1) WO2021013783A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022243210A1 (en) * 2021-05-17 2022-11-24 F. Hoffmann-La Roche Ag sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316757A (en) 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US5342606A (en) 1984-10-18 1994-08-30 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
EP0265519B1 (en) 1986-04-30 1995-09-13 IGEN, INC. (a California corporation) Electrochemiluminescent assays
US5591581A (en) 1986-04-30 1997-01-07 Igen, Inc. Electrochemiluminescent rhenium moieties and methods for their use
KR0143993B1 (ko) 1988-11-03 1998-07-15 리차아드 제이 매씨이 전기화학 발광성 분석
WO1990005296A1 (en) 1988-11-03 1990-05-17 Igen, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
IL100867A (en) 1991-02-06 1995-12-08 Igen Inc Method and device for improved luminescence testing
US5480990A (en) 1991-12-10 1996-01-02 The Dow Chemical Company Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents
US5739294A (en) 1991-12-10 1998-04-14 The Dow Chemical Company Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
ZA929351B (en) 1991-12-11 1993-06-04 Igen Inc Electrochemiluminescent label for DNA assays.
US5462725A (en) 1993-05-06 1995-10-31 The Dow Chemical Company 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5385893A (en) 1993-05-06 1995-01-31 The Dow Chemical Company Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5834461A (en) 1993-07-29 1998-11-10 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
CA2172248C (en) 1993-09-22 2003-12-30 John Kenten Self-sustained sequence replication electrochemiluminescent nucleic acid assay
AU703344B2 (en) 1994-08-26 1999-03-25 Igen International, Inc. Biosensor for and method of electrogenerated chemiluminescent detection of nucleic acid adsorbed to a solid surface
US5786141A (en) 1994-08-26 1998-07-28 Bard; Allen J. Electrogenerated chemiluminescence labels for analysis and/or referencing
US6852502B1 (en) 1995-06-06 2005-02-08 Bioveris Corporation Electrochemiluminescent enzyme biosensors
US5643713A (en) 1995-06-07 1997-07-01 Liang; Pam Electrochemiluminescent monitoring of compounds
WO1996033411A1 (en) 1995-04-18 1996-10-24 Igen, Inc. Electrochemiluminescence of rare earth metal chelates
US5679519A (en) 1995-05-09 1997-10-21 Oprandy; John J. Multi-label complex for enhanced sensitivity in electrochemiluminescence assay
AU718767B2 (en) 1995-06-07 2000-04-20 Bioveris Corporation Electrochemiluminescent enzyme immunoassay
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP2637020A3 (en) * 2007-06-29 2014-01-08 Correlogic Systems Inc. Predictive markers for ovarian cancer
US8367332B2 (en) 2008-10-31 2013-02-05 Case Western Reserve University Detection and quantification of abasic site formation in vivo
EP2673284B1 (en) 2011-02-09 2017-08-30 Roche Diagnostics GmbH New iridium-based complexes for ecl
TW201401798A (zh) 2012-06-28 2014-01-01 Chunghwa Telecom Co Ltd ＦＴＴｘ光終端設備之用戶端動態多路由饋電系統
WO2014091580A1 (ja) 2012-12-12 2014-06-19 株式会社東芝 クラウドシステム管理装置、クラウドシステム、再配置方法、及びプログラム
JP5922639B2 (ja) 2013-12-07 2016-05-24 レノボ・シンガポール・プライベート・リミテッド 折り畳み式の電子機器、表示システム、および表示方法
US9716942B2 (en) 2015-12-22 2017-07-25 Bose Corporation Mitigating effects of cavity resonance in speakers

Also Published As

Publication number Publication date
US20220137069A1 (en) 2022-05-05
JP2022541312A (ja) 2022-09-22
WO2021013783A1 (en) 2021-01-28
EP4004552A1 (en) 2022-06-01
CN114144671A (zh) 2022-03-04
KR20220024699A (ko) 2022-03-03
JP7315781B2 (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
BR112013033488B8 (pt) Métodos para facilitar o diagnóstico do comprometimento cognitivo devido a doença de alzheimer ou comprometimento cognitivo leve (mci)e kit
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
BR112015016231A8 (pt) método para identificar um sujeito em risco de ou tendo um distúrbio mediado por pkal, método para avaliar um tratamento de um distúrbio mediado por pkal em um sujeito, método para tratar uma doença mediada por pkal, composição farmacêutica para uso no tratamento de uma doença mediada por pkal de um sujeito e método para determinar um valor de cininogênio clivado, cininogênio intacto ou ambos, em uma amostra
BR112018070971A2 (pt) métodos e kits para a diagnose e estratificação de risco de pacientes com isquemia
ATE518007T1 (de) Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
BRPI0507442A (pt) métodos de diagnóstico e tratamento de pré-eclampsia ou eclampsia
BR112017021305A2 (pt) dispositivo de teste de fluxo lateral, e, método e kit para detecção quantitativa de um analito em uma amostra de saliva
EA201992026A1 (ru) Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5
BR112017022320A2 (pt) métodos para tratamento de câncer de pulmão
AR060857A1 (es) Deteccion de enfermedades venosas tromboembolicas por la dosificacion de los d-dimeros y de la fibrina soluble
PH12016500302A1 (en) Compositions and method for treating complement-associated conditions
BR112019025056A2 (pt) Inibidores de fgfr2 para o tratamento de colangiocarcinoma
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
WO2020055954A3 (en) Methods for detecting liver diseases
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
BR112023000892A2 (pt) Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor
WO2021067850A3 (en) METHODS OF DETECTING circRNA
BR112022001140A2 (pt) Métodos para avaliar se um paciente tem endometriose ou está em risco de desenvolver endometriose, selecionar um paciente para terapia e monitorar um paciente que sofre de endometriose ou que está sendo tratado para endometriose
BR112019000199A2 (pt) adrenomedulina para avaliar a congestão em um indivíduo com insuficiência cardíaca aguda
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
BR112017012287A2 (pt) uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
BR112019001446A2 (pt) edição de rna como biomarcadores para teste de transtornos de humor
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis